A Phase 1 interventional study of MK-8266 0.1 mg and MK-8266 1.0 mg in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 28th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2009, is one of 17 in phase 1, and was the 15th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 84 across the 32 interventional studies, 450 across the 1 observational. Of the 33 that completed or were terminated, 27 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 33 studies in Hypertension by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A three panel study, to determine if MK-8266 given as a single dose is sufficiently safe and well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of subjects with mild to moderate hypertension. The primary hypotheses for the study are that MK-8266 given as single doses is sufficiently safe and well tolerated to permit continued clinical investigation in healthy young male volunteers and male participants with mild-to-moderate hypertension and that in males with mild to moderate hypertension, at a single oral dose of MK-8266 that is sufficiently safe and well-tolerated, postdose mean time-weighted average across 24 hours of aortic augmentation index (TWA0-12hrs AIx) is reduced compared to placebo. A mean decrease of ≥ 5 percentage points is considered clinically meaningful.
Three panels, each consisting of either 8 or 9 participants (8 healthy young males in Panel A and Panel B; and 9 participants with mild to moderate hypertension in Panel C) will be randomized to receive either MK-8266 or matching placebo in either a 6:2 ratio (Panel A and Panel B) or 6:3 ratio (Panel C), respectively, in up to 5 treatment (1 to 5) periods in Panel A and up to 4 treatment (1 to 4) periods in Panel B and Panel C. In all panels, doses will be escalated in a rising, fixed sequence. Some participants took study drug after fasting and some with food.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg
MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg
Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg
Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
Drug: MK-8266 0.1 mg · Drug: MK-8266 1.0 mg · Drug: Placebo
Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Also known as: MK-8266
MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Number of Participants Who Experienced One or More Adverse Events
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
Time frame: Up to 14 days after administration of last dose of study drug in each study period (Up to 43 Days)
Number of Participants Who Discontinued Study Drug Due to an AE
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
Time frame: Up to 43 days
Aortic Augmentation Index - Time-Weighted Average 0-24 Hours
Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.
Time frame: Predose, 1.5, 3, 12, and 24 hours postdose
MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-inf\] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC\[0-inf\] was not collected, analyzed or summarized for participants receiving placebo.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
MK-8266 PK Parameter Apparent t1/2
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-24 hours\] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 postdose
Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.
Time frame: Predose, 0.5, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours postdose
Time-Weighted Average of Heart Rate (0-12 Hours)
HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
Time frame: Up to 12 hours
Participants were recruited at 2 clinical study sites in Germany and in Belgium.
| Milestone | Panel A, Healthy Male Participants, Sequence 1 | Panel A, Healthy Male Participants, Sequence 2 | Panel A, Healthy Male Participants, Sequence 3 | Panel A, Healthy Male Participants, Sequence 4 | Panel B, Healthy Male Participants, Sequence 1 | Panel B, Healthy Male Participants, Sequence 2 | Panel B, Healthy Male Participants, Sequence 3 | Panel B, Healthy Male Participants, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 1 | Panel C, Mild/Moderate Hypertension, Sequence 2 | Panel C, Mild/Moderate Hypertension, Sequence 3 | Panel C, Mild/Moderate Hypertension, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 5 | Panel C, Mild/Moderate Hypertension, Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A, Healthy Male Participants, Sequence 1 | Panel A, Healthy Male Participants, Sequence 2 | Panel A, Healthy Male Participants, Sequence 3 | Panel A, Healthy Male Participants, Sequence 4 | Panel B, Healthy Male Participants, Sequence 1 | Panel B, Healthy Male Participants, Sequence 2 | Panel B, Healthy Male Participants, Sequence 3 | Panel B, Healthy Male Participants, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 1 | Panel C, Mild/Moderate Hypertension, Sequence 2 | Panel C, Mild/Moderate Hypertension, Sequence 3 | Panel C, Mild/Moderate Hypertension, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 5 | Panel C, Mild/Moderate Hypertension, Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A, Healthy Male Participants, Sequence 1 | Panel A, Healthy Male Participants, Sequence 2 | Panel A, Healthy Male Participants, Sequence 3 | Panel A, Healthy Male Participants, Sequence 4 | Panel B, Healthy Male Participants, Sequence 1 | Panel B, Healthy Male Participants, Sequence 2 | Panel B, Healthy Male Participants, Sequence 3 | Panel B, Healthy Male Participants, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 1 | Panel C, Mild/Moderate Hypertension, Sequence 2 | Panel C, Mild/Moderate Hypertension, Sequence 3 | Panel C, Mild/Moderate Hypertension, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 5 | Panel C, Mild/Moderate Hypertension, Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A, Healthy Male Participants, Sequence 1 | Panel A, Healthy Male Participants, Sequence 2 | Panel A, Healthy Male Participants, Sequence 3 | Panel A, Healthy Male Participants, Sequence 4 | Panel B, Healthy Male Participants, Sequence 1 | Panel B, Healthy Male Participants, Sequence 2 | Panel B, Healthy Male Participants, Sequence 3 | Panel B, Healthy Male Participants, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 1 | Panel C, Mild/Moderate Hypertension, Sequence 2 | Panel C, Mild/Moderate Hypertension, Sequence 3 | Panel C, Mild/Moderate Hypertension, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 5 | Panel C, Mild/Moderate Hypertension, Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Panel A, Healthy Male Participants, Sequence 1 | Panel A, Healthy Male Participants, Sequence 2 | Panel A, Healthy Male Participants, Sequence 3 | Panel A, Healthy Male Participants, Sequence 4 | Panel B, Healthy Male Participants, Sequence 1 | Panel B, Healthy Male Participants, Sequence 2 | Panel B, Healthy Male Participants, Sequence 3 | Panel B, Healthy Male Participants, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 1 | Panel C, Mild/Moderate Hypertension, Sequence 2 | Panel C, Mild/Moderate Hypertension, Sequence 3 | Panel C, Mild/Moderate Hypertension, Sequence 4 | Panel C, Mild/Moderate Hypertension, Sequence 5 | Panel C, Mild/Moderate Hypertension, Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
| Participants | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | Pooled Placebo (Panels A, B, C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced One or More Adverse Events | 2 | 3 | 5 | 2 | 3 | 1 | 4 | 3 | 2 | 3 | 4 | 6 | 3 | 10 |
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
| Participants | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | Pooled Placebo (Panels A, B, C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Central ascending aortic blood pressure augmentation index (AIx) is the percentage of the central pulse pressure attributed to the reflected pulse wave, and is an indirect measure of systemic arterial stiffness. AIx can be measured non-invasively by radial tonometry using aplanation tonometry of radial artery with the SphygmoCor Pulse Wave Analysis System Guide (SphygmoCor system). AIx was performed at prestudy to ensure an adequate waveform can be obtained. At each time point, a minimum of 2 AIx were completed in an attempt to obtain 2 acceptable quality assessments. A time weighted average was calculated. AIx was adjusted for heart rate. A decrease in the AIx of ≥5 percentage is considered clinically meaningful. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period. The 12-hour measurement was not collected (per protocol) in all periods of Panels A and B.
| Percentage of central pulse pressure | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel A Placebo | Pooled Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B Placebo | Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. | Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | Panel C Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aortic Augmentation Index - Time-Weighted Average 0-24 Hours | -8.79 ± 9.66 | -2.96 ± 9.15 | -1.73 ± 4.49 | -7.42 ± 3.85 | -5.70 ± 7.57 | -1.73 ± 7.36 | -13.1 ± 8.71 | -14.1 ± 7.49 | -16.7 ± 5.21 | -15.3 ± 2.68 | 8.43 ± 4.98 | 11.29 ± 6.60 | 7.78 ± 11.10 | 8.74 ± 3.90 | 17.74 ± 6.75 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-inf\] is a measure of the mean concentration levels of drug in the plasma after the dose. AUC\[0-inf\] was not collected, analyzed or summarized for participants receiving placebo.
| mg/mL*hr | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8266 Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) | — | — | — | 264 ± 64.4 | 441 ± 105 | — | 216 ± 55.95 | 350 ± 49.5 | — | — | — | 528 ± 151 | 623 ± 350 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. For Panel A 1.0/0.8 mg MK-8266, the second dose was not well characterized due to limited sampling. Observed exposure likely underestimates the true exposure. Cmax was not collected, analyzed or summarized for participants receiving placebo.
| nM | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Observed Maximum (Peak) Plasma Concentration (Cmax) | 2.28 ± 0.291 | 4.33 ± 0.454 | 11.4 ± 0.819 | 22.2 ± 3.40 | 20.5 ± 2.58 | 7.46 ± 1.41 | 19.5 ± 5.14 | 21.3 ± 4.16 | 7.71 ± 2.64 | 19.1 ± 3.77 | 22.1 ± 3.06 | 21.7 ± 3.80 | 22.4 ± 3.59 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. Tmax was not collected, analyzed or summarized for participants receiving placebo.
| Hours | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Observed Time to Reach Cmax (Tmax) | 2.5 (1.5 to 4.0) | 4.0 (3.0 to 4.0) | 3.5 (2.0 to 4.0) | 4.0 (3.0 to 4.0) | 3.5 (2.0 to 8.0) | 3.0 (2.0 to 4.0) | 4.0 (2.0 to 6.0) | 3.0 (2.0 to 4.0) | 1.5 (1.5 to 6.0) | 3.0 (2.0 to 10.0) | 5.0 (3.0 to 10.0) | 6.5 (2.0 to 15.0) | 9.0 (3.0 to 15.0) |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. t1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. Harmonic means +/- Pseudo standard deviations are displayed. t1/2 was not collected, analyzed or summarized for participants receiving placebo.
| Hours | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK- 8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK- 8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MK-8266 PK Parameter Apparent t1/2 | — | — | — | 13.6 ± 2.6 | 11.7 ± 2.2 | — | 9.2 ± 3.5 | 12.0 ± 3.0 | — | — | — | 10.4 ± 2.2 | 12.8 ± 4.8 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-24 hours\] is a measure of the mean concentration levels of drug in the plasma after the dose. The Fed Group was administered a high fat meal.
| nM·hr | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) |
|---|---|---|
| Effect of Food on MK-8266 PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24hr) Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants | 59.6 (38.9 to 91.2) | 52.9 (34.6 to 81.0) |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. The Fed Group was administered a high fat meal.
| nM | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) |
|---|---|---|
| Effect of Food on MK-8266 PK Parameter Cmax Following Administration of Single Oral Doses of MK-8266 at 0.4 mg to Healthy Male Participants | 7.5 (5.2 to 11.0) | 7.3 (5.0 to 10.6) |
HR was measured with a validated automatic measuring device. Time weighted average was obtained as follows: For all HR values obtained over the 12-hour observation period, multiply the length of time that the participant spent at each HR value by that HR value, add these products together, and then divide by duration of the observation period. The length of time spent at an identified HR value was defined as the time elapsed since previous post-dose measurement, or time elapsed since drug administration, if there is no previous post-dose measurement. Participants in Arms/Groups in which MK-8266 or placebo was administered in more than one period were counted separately for each period.
| Beats per Minute | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel A Placebo | Pooled Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B Placebo | Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. | Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | Panel C Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time-Weighted Average of Heart Rate (0-12 Hours) | 58.79 ± 6.71 | 61.65 ± 3.06 | 56.36 ± 4.86 | 66.40 ± 7.90 | 63.71 ± 3.17 | 59.32 ± 6.28 | 57.38 ± 5.92 | 61.07 ± 5.04 | 59.92 ± 10.23 | 56.53 ± 6.66 | 69.82 ± 8.09 | 66.40 ± 9.82 | 64.14 ± 7.40 | 64.90 ± 8.33 | 60.66 ± 8.07 |
Collected over Up to 14 days after administration of the last dose of study drug (Up to 43 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A MK-8266 0.1 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Panel A MK-8266 0.2 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel A MK-8266 0.5 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel A MK-8266 1.0 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Panel A MK-8266 1.0/0.8 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel B MK-8266 0.4 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Panel B MK-8266 1.2 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel B MK-8266 1.2/0.6 mg (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel B MK-8266 0.4 mg Fed (Healthy Males) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Pooled Placebo (Panels A, B, C) | 0/23 (0%) | 0/23 (0%) | 10/23 (43.5%) |
| Event | Panel A MK-8266 0.1 mg (Healthy Males) | Panel A MK-8266 0.2 mg (Healthy Males) | Panel A MK-8266 0.5 mg (Healthy Males) | Panel A MK-8266 1.0 mg (Healthy Males) | Panel A MK-8266 1.0/0.8 mg (Healthy Males) | Panel B MK-8266 0.4 mg (Healthy Males) | Panel B MK-8266 1.2 mg (Healthy Males) | Panel B MK-8266 1.2/0.6 mg (Healthy Males) | Panel B MK-8266 0.4 mg Fed (Healthy Males) | Panel C MK-8266 1.0/0.8 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.2/1.0 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/0.6/0.6 mg (Mild/Mod. Hypertension) | Panel C MK-8266 1.0/1.0/0.6 mg (Mild/Mod. Hypertension) | Pooled Placebo (Panels A, B, C) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 3/6 | 4/6 | 1/6 | 1/6 | 1/6 | 1/6 | 1/6 | 0/6 | 2/6 | 3/6 | 5/6 | 3/6 | 6/23 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 0/6 | 1/6 | 1/6 | 0/23 |
| Abdominal discomfortGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/23 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/23 |
| Aphthous stomatitisGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/23 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/23 |
| ToothacheGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/23 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 0/23 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/23 |
| Age, Continuous(Years) | Panel A MK-8266 (Healthy Males) | Panel B MK-8266 (Healthy Males) | Panel C MK-8266 (Mild/Mod. Hypertension) | Total |
|---|---|---|---|---|
| Mean | 34.3 ± 8.1 | 27.3 ± 5.4 | 47.3 ± 3.9 | 36.7 ± 10.4 |
| Sex: Female, Male(Participants) | Panel A MK-8266 (Healthy Males) | Panel B MK-8266 (Healthy Males) | Panel C MK-8266 (Mild/Mod. Hypertension) | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 9 | 25 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Nov 2009 to primary completion in May 2010, 5 months.
Results were first posted in Feb 2019, 8 years 9 months after primary completion.
Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 5 months is above that.
Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-8266